Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus Gemcitabine in K-RAS wild-type pancreatic cancer
NCT02395016Phase 3Completed
- Start
- Apr 2015
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in pancreatic cancer (PC). Started Apr 2015; status: completed.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02395016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395016.